Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Daniel O. Persky, MD1; Hongli Li, MS2; Deborah M. Stephens, DO3; Steven I. Park, MD4,5; Nancy L. Bartlett, MD6; Lode J. Swinnen, MD7; Paul M. Barr, MD8; Jerome D. Winegarden III, MD9; Louis S. Constine, MD10; Thomas J. Fitzgerald, MD11; John P. Leonard, MD12; Brad S. Kahl, MD6; Michael L. LeBlanc, PhD2; Joo Y. Song, MD13; Richard I. Fisher, MD14; Lisa M. Rimsza, MD15; Sonali M. Smith, MD16; Thomas P. Miller, MD1; and Jonathan W.
ORLANDO — Nearly 90% of patients with limited-stage diffuse large B-cell lymphoma maintained excellent outcomes after four cycles of R-CHOP with PET-directed therapy, according to study findings presented at ASH Annual Meeting and Exposition. Patients with non-bulky stage I/II untreated DLBCL received standard R-CHOP therapy and an interim PET scan on day 15-18 of cycle 3, according to the abstract.
Purpose Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Subsequent analysis showed an unexpected overlap of the PFS curves.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
